Huawei CEO Ren Zhengfei laid out plans to bring more efficiencies to the organization. This included simplifying the reporting structure, cutting down on surplus staff, axing...Technologyread more
The bond market has entered a financial twilight zone, and at this point, there doesn't seem to be a smooth way out.Market Insiderread more
China has used both monetary and fiscal measures to lift economic activity as its trade war with the U.S. looks set to intensify in the coming months.China Economyread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
"I think (rate cuts) will help, but whether they're going to be sufficient to counter the negative trade pressures and global growth slowdown and impact is debatable," one...Central Banksread more
Chinese overseas investment growth will likely slow or even decline in the next few years as risks around the world increase, according to new research by Moody's Investors...China Economyread more
The two countries want to smash the civil aerospace duopoly enjoyed by Airbus and Boeing.Aerospace & Defenseread more
Alibaba held a board meeting before its latest quarterly earnings release last week, during which the board decided to postpone the Hong Kong listing, Reuters reported.Technologyread more
Federal Reserve Chairman Jerome Powell is set to deliver his annual speech on Friday at the Jackson Hole, Wyoming symposium, where he's expected to provide more clarity on the...Asia Marketsread more
U.S. and Asian investors poured $3.7 billion into U.K. tech start-ups in the first seven months of 2019, research shows.Technologyread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
In fact, Cramer has been in a heated love affair with biotech for more than 30 years. While you don't get a rally from them every day, he thinks they are more reliable than any other group.
"Never stop loving biotech. That's been my mantra since the 1980s, and every day I thank my lucky stars that I haven't abandoned the concept or the stocks," the "Mad Money" host said.
Tuesday was one of those days that served as a reminder that the love is still in the air. Especially when Biogen Idec's stock soared on a positive Alzheimer's study that has improved cognition significantly in just 54 weeks, taking the drug right into Phase 3 testing.
This company was one of the first stocks the "Mad Money" host bought when Genentech, Amgen and Biogen basically invented the biotech genre.
"When one of these stocks flies, the whole group tends to fly, in part because they are tightly correlated by moronic ETF's that take up the good with the bad. Fortunately, there are enough goods in the basket to overwhelm the bad."
That is why Cramer never minds when Regeneron and Celgene move up with whatever flavor of the day news is released. Though many think that these stocks are one-trick ponies, the reality is that they always seem to have something up their sleeves.
Regeneron is pumping out new formulations constantly, especially for cholesterol and asthma. Celgene is a breeding ground for treatments for psoriatic arthritis and cancers. It also has a stake in one of Cramer's faves, Agios Pharma, which is testing a formula to kill cancer cells without infusing the entire body with toxins.
Though Agios has had a huge run with gobs of profit taking, and it may already be late in the game, Cramer wouldn't be surprised if Celgene buys the 85 percent of Agios that it doesn't already own.
Another reminder of biotech love seen on Tuesday was a 12 percent gain for Avanir Pharmaceuticals on news that Japanese company Otsuka agreed to buy it for $3.5 billion. And that's a cherry on top of the 400 percent gain Avanir already clocked, year-to-date.
Read more from Mad Money with Jim Cramer
Cramer Remix: What falling oil means to you
Cramer talks crude chaos with CEO
Cramer's worst case oil scenarios
"In an era when you are buffeted by cyclical headwinds … it's comforting to know that you can own a biotech and get hit with the kind of lightning that can make your year," Cramer said.
It won't happen every day, but the love shows up more often than most other angry cohorts, which is why Cramer thinks you should love biotech, too.